/LUMO
LUMO Stock - Lumos Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$4.34+0.00%
+$0.00 (+0.00%) • Dec 11
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+280.2%upside
Target: $16.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LUMO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.30 – $4.38
TARGET (TP)$16.50
STOP LOSS$3.99
RISK/REWARD1:34.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.33
52W High$4.58
52W Low$1.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $2.05M | $1.52M | $230,000 | $168,000 | $936,000 |
| Gross Profit | $2.05M | $1.47M | $230,000 | $168,000 | $899,000 |
| Gross Margin | 100.0% | 96.8% | 100.0% | 100.0% | 96.0% |
| Operating Income | $-36,614,000 | $-32,040,000 | $-31,347,000 | $-26,303,000 | $-45,134,000 |
| Net Income | $-34,034,000 | $-31,062,000 | $-30,430,000 | $-5,663,000 | $-42,989,000 |
| Net Margin | -1659.4% | -2039.5% | -13230.4% | -3370.8% | -4592.8% |
| EPS | $-4.18 | $-3.71 | $-3.65 | $-0.84 | $-10.39 |
Company Overview
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LUMOBeat Rate
65%
Last 20 quarters
Avg Surprise
+16.1%
EPS vs Estimate
Beats / Misses
13/6
1 met exactly
Latest EPS
$-0.90
Q4 2024
EPS Surprise History
Q1 23
-3.2%
$-0.98vs$-0.95
Q2 23
+20.5%
$-0.89vs$-1.12
Q3 23
-2.8%
$-1.09vs$-1.06
Q4 23
+5.5%
$-1.04vs$-1.10
Q1 24
+0.8%
$-1.17vs$-1.18
Q2 24
-6.6%
$-1.29vs$-1.21
Q3 24
+26.2%
$-0.93vs$-1.26
Q4 24
-60.7%
$-0.90vs$-0.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 7, 2024 | $-0.56 | $-0.90 | -60.7% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-1.26 | $-0.93 | +26.2% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.21 | $-1.29 | -6.6% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-1.18 | $-1.17 | +0.8% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-1.10 | $-1.04 | +5.5% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-1.06 | $-1.09 | -2.8% | ✗ MISS |
Q2 2023 | May 3, 2023 | $-1.12 | $-0.89 | +20.5% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-0.95 | $-0.98 | -3.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.01 | $-0.86 | +14.9% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.98 | $-0.94 | +4.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.92 | $-0.92 | 0.0% | = MET |
Q1 2022 | Mar 10, 2022 | $-0.92 | $-0.68 | +26.1% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-1.06 | $-0.90 | +15.1% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-1.01 | $-1.04 | -3.0% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-0.85 | $-1.04 | -22.4% | ✗ MISS |
Q1 2021 | Mar 9, 2021 | $-0.85 | $-0.31 | +63.5% | ✓ BEAT |
Q4 2020 | Nov 10, 2020 | $-0.64 | $0.21 | +132.8% | ✓ BEAT |
Q3 2020 | Aug 13, 2020 | $-0.70 | $-0.65 | +7.1% | ✓ BEAT |
Q2 2020 | May 28, 2020 | $-0.83 | $-0.14 | +83.1% | ✓ BEAT |
Q1 2020 | Feb 28, 2020 | $-2.52 | $-1.98 | +21.4% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about LUMO
What is LUMO's current stock price?
Lumos Pharma, Inc. (LUMO) is currently trading at $4.34 per share. The stock has moved +0.00% today.
What is the analyst price target for LUMO?
The average analyst price target for LUMO is $16.50, based on 1 analyst.
What sector is Lumos Pharma, Inc. in?
Lumos Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LUMO's market cap?
Lumos Pharma, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does LUMO pay dividends?
No, Lumos Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERC
Cerecor Inc.
$2.93
Mkt Cap: $0.0B
EYEN
Eyenovia, Inc.
$7.56
Mkt Cap: $0.0B
GRCE
Grace Therapeutics, Inc.
$3.40
Mkt Cap: $0.0B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
MGTA
Magenta Therapeutics, Inc.
$0.70
Mkt Cap: $0.0B
ORKA
Oruka Therapeutics, Inc.
$31.84
Mkt Cap: $1.2B
PSTI
Pluristem Therapeutics Inc.
$1.00
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
STSA
Satsuma Pharmaceuticals, Inc.
$1.10
Mkt Cap: $0.0B
Explore stocks similar to LUMO for comparison